Back to News
Market Impact: 0.3
What Biodesix (BDSX) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Biodesix reported 10% revenue growth in Q3 2026, but results fell short of its expectations. The company cited a smaller-than-planned sales force, seasonal patterns in primary care and delayed customer projects as factors weighing on performance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
BDSX-0.45
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook